# Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

> **NCT01908478** · PHASE1 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 34 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Veliparib
- **DRUG:** Gemcitabine
- **RADIATION:** Intensity modulated radiation therapy

## Key facts

- **NCT ID:** NCT01908478
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-02
- **Primary completion:** 2017-07-14
- **Final completion:** 2020-07-06
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2020-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01908478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01908478, "Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01908478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*